Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biodesix, Inc. stock logo
BDSX
Biodesix
$20.38
-3.1%
$18.68
$5.26
$24.92
$217.78M0.5368,277 shs41,089 shs
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
$20.35
+2.3%
$15.23
$5.26
$86.00
$59.59M0.683,455 shs5,598 shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$3.64
-5.2%
$4.48
$2.56
$12.72
$185.71M1.99797,231 shs695,382 shs
Exagen Inc. stock logo
XGN
Exagen
$4.35
-2.2%
$4.55
$2.59
$12.23
$107.51M2.02221,657 shs188,560 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biodesix, Inc. stock logo
BDSX
Biodesix
-3.09%-4.72%-14.41%+85.61%+162.56%
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
+2.26%+42.41%+40.10%+40.06%-68.98%
LifeMD, Inc. stock logo
LFMD
LifeMD
-5.21%-6.19%-13.33%-22.22%-64.31%
Exagen Inc. stock logo
XGN
Exagen
-2.25%-11.94%-8.42%+50.00%-48.52%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biodesix, Inc. stock logo
BDSX
Biodesix
$20.38
-3.1%
$18.68
$5.26
$24.92
$217.78M0.5368,277 shs41,089 shs
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
$20.35
+2.3%
$15.23
$5.26
$86.00
$59.59M0.683,455 shs5,598 shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$3.64
-5.2%
$4.48
$2.56
$12.72
$185.71M1.99797,231 shs695,382 shs
Exagen Inc. stock logo
XGN
Exagen
$4.35
-2.2%
$4.55
$2.59
$12.23
$107.51M2.02221,657 shs188,560 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biodesix, Inc. stock logo
BDSX
Biodesix
-3.09%-4.72%-14.41%+85.61%+162.56%
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
+2.26%+42.41%+40.10%+40.06%-68.98%
LifeMD, Inc. stock logo
LFMD
LifeMD
-5.21%-6.19%-13.33%-22.22%-64.31%
Exagen Inc. stock logo
XGN
Exagen
-2.25%-11.94%-8.42%+50.00%-48.52%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biodesix, Inc. stock logo
BDSX
Biodesix
2.80
Moderate Buy$28.3339.03% Upside
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
2.00
Hold$55.00170.27% Upside
LifeMD, Inc. stock logo
LFMD
LifeMD
2.60
Moderate Buy$9.14151.18% Upside
Exagen Inc. stock logo
XGN
Exagen
2.89
Moderate Buy$9.00106.90% Upside

Current Analyst Ratings Breakdown

Latest EUDA, BDSX, LFMD, and XGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
LifeMD, Inc. stock logo
LFMD
LifeMD
DowngradeHoldStrong Sell
6/24/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
Initiated CoverageBuy$32.00
6/24/2026
Exagen Inc. stock logo
XGN
Exagen
Initiated CoverageBuy$8.00
6/24/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
UpgradeStrong-Buy
6/24/2026
Exagen Inc. stock logo
XGN
Exagen
UpgradeStrong-Buy
6/18/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
Boost Price TargetBuy$22.00 ➝ $27.00
6/15/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
Initiated CoverageBuy$26.00
6/15/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
Initiated CoverageBuy$26.00
6/12/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
UpgradeSell (E+)Sell (D-)
5/27/2026
LifeMD, Inc. stock logo
LFMD
LifeMD
Reiterated RatingBuy
5/26/2026
LifeMD, Inc. stock logo
LFMD
LifeMD
Reiterated RatingBuy$10.00
(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biodesix, Inc. stock logo
BDSX
Biodesix
$88.50M2.39N/AN/A($0.31) per share-65.74
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
$6.82M8.92N/AN/A($2.26) per share-9.00
LifeMD, Inc. stock logo
LFMD
LifeMD
$194.05M0.91N/AN/A$0.48 per share7.58
Exagen Inc. stock logo
XGN
Exagen
$66.57M1.58N/AN/A$0.77 per share5.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biodesix, Inc. stock logo
BDSX
Biodesix
-$35.26M-$4.06N/AN/AN/A-33.26%-2,101.40%-35.65%8/5/2026 (Estimated)
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
-$2.77MN/AN/AN/AN/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
$14.35M$0.0572.8120.22N/A2.37%-150.88%-22.59%8/5/2026 (Estimated)
Exagen Inc. stock logo
XGN
Exagen
-$19.95M-$0.89N/AN/AN/A-29.49%-94.37%-28.96%8/4/2026 (Estimated)

Latest EUDA, BDSX, LFMD, and XGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Biodesix, Inc. stock logo
BDSX
Biodesix
-$0.86N/AN/AN/A$26.03 millionN/A
8/5/2026Q2 2026
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.1457N/AN/AN/A$49.16 millionN/A
8/4/2026Q2 2026
Exagen Inc. stock logo
XGN
Exagen
-$0.19N/AN/AN/A$17.80 millionN/A
5/11/2026Q1 2026
Exagen Inc. stock logo
XGN
Exagen
-$0.24-$0.17+$0.07-$0.17$16.41 million$17.31 million
5/6/2026Q1 2026
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.14-$0.20-$0.06-$0.20$48.84 million$50.16 million
5/5/2026Q4 2025
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
-$1.20-$0.44+$0.76-$0.44$3.90 million$1.92 million
5/4/2026Q1 2026
Biodesix, Inc. stock logo
BDSX
Biodesix
-$1.1298-$0.81+$0.3198-$0.81$23.12 million$25.56 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biodesix, Inc. stock logo
BDSX
Biodesix
N/AN/AN/AN/AN/A
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
N/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
N/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biodesix, Inc. stock logo
BDSX
Biodesix
5.09
2.82
2.82
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
N/A
0.18
0.18
LifeMD, Inc. stock logo
LFMD
LifeMD
N/A
1.04
0.98
Exagen Inc. stock logo
XGN
Exagen
1.67
3.47
3.47

Institutional Ownership

CompanyInstitutional Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
20.96%
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
4.35%
LifeMD, Inc. stock logo
LFMD
LifeMD
35.52%
Exagen Inc. stock logo
XGN
Exagen
75.25%

Insider Ownership

CompanyInsider Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
23.20%
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
N/A
LifeMD, Inc. stock logo
LFMD
LifeMD
17.22%
Exagen Inc. stock logo
XGN
Exagen
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biodesix, Inc. stock logo
BDSX
Biodesix
22010.36 million7.95 millionNo Data
EUDA Health Holdings Limited stock logo
EUDA
EUDA Health
22.99 millionN/ANot Optionable
LifeMD, Inc. stock logo
LFMD
LifeMD
23048.36 million40.04 millionOptionable
Exagen Inc. stock logo
XGN
Exagen
22024.16 million21.65 millionOptionable

Recent News About These Companies

Exagen (XGN) Projected to Release Earnings on Tuesday
Exagen Inc. to Participate in Upcoming Investor Conference
Exagen to Announce Second Quarter Financial Results on August 4, 2026
Exagen Earnings Call Highlights Growth Amid Key Risks
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Inc. Reports First Quarter 2026 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biodesix stock logo

Biodesix NASDAQ:BDSX

$20.38 -0.65 (-3.09%)
Closing price 07/29/2026 04:00 PM Eastern
Extended Trading
$21.00 +0.62 (+3.04%)
As of 07/29/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

EUDA Health stock logo

EUDA Health NASDAQ:EUDA

$20.35 +0.45 (+2.26%)
Closing price 07/29/2026 03:59 PM Eastern
Extended Trading
$20.59 +0.24 (+1.16%)
As of 07:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.

LifeMD stock logo

LifeMD NASDAQ:LFMD

$3.64 -0.20 (-5.21%)
Closing price 07/29/2026 04:00 PM Eastern
Extended Trading
$3.65 +0.01 (+0.16%)
As of 07:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

Exagen stock logo

Exagen NASDAQ:XGN

$4.35 -0.10 (-2.25%)
Closing price 07/29/2026 04:00 PM Eastern
Extended Trading
$4.35 0.00 (0.00%)
As of 07/29/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.